Fighting pulmonary infections
Research on bacterial pulmonary infections
Bacterial antibiotic resistance
The bacteria responsible for pulmonary infections are increasingly resistant to antibiotics. To find new solutions, scientists from Institut Pasteur are working with Cochin hospital, conducting research on new molecules capable of combating these bacteria. The results obtained are of particular interest to patients suffering from cystic fibrosis, who are most vulnerable to respiratory infections caused by multi-drug resistant bacteria.
Antimicrobial Peptides, an alternative to antibiotics
Antimicrobial Peptides (AMP) are proteins with the potential to be an alternative therapy to antibiotics. Two families of AMPs have been identified for their antibacterial activity on pulmonary bacteria in humans. Institut Pasteur's research project involves studying the specific action of these AMPs on the bacteria responsible for pneumonia and nosocomial infections. Part of this work will be carried out on isolated strains of bacteria in patients suffering from cystic fibrosis. Particular attention will be paid to the capacity of these AMPs to eradicate these bacteria in patients suffering from cystic fibrosis.
The contribution of the Air Liquide Foundation
The Air Liquide Foundation is donating €50,000 for the acquisition of the equipment required for the research project; namely a device for the exact characterization of the genes expressed, as well as reagents for cell and bacteria cultures.
PROJECT IDENTITY
- Project initiator: Institut Pasteur, Paris
- Location: Paris, France
- Year of support: 2016
- Air Liquide Sponsor: Marc Lemaire - Air Liquide Healthcare International R&D Manager, Paris-Saclay Research Center
